Boston Partners Cuts Stock Position in Henry Schein, Inc. (NASDAQ:HSIC)

Boston Partners cut its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 95.2% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 125,566 shares of the company’s stock after selling 2,511,863 shares during the quarter. Boston Partners owned approximately 0.10% of Henry Schein worth $9,010,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. Mather Group LLC. bought a new stake in Henry Schein during the 1st quarter valued at approximately $97,000. Palisade Asset Management LLC bought a new stake in shares of Henry Schein during the first quarter valued at approximately $113,000. Benjamin F. Edwards & Company Inc. lifted its holdings in shares of Henry Schein by 37.8% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 1,516 shares of the company’s stock worth $114,000 after buying an additional 416 shares in the last quarter. Covestor Ltd boosted its position in shares of Henry Schein by 12.8% during the first quarter. Covestor Ltd now owns 1,511 shares of the company’s stock worth $114,000 after acquiring an additional 171 shares during the last quarter. Finally, GAMMA Investing LLC bought a new position in shares of Henry Schein during the fourth quarter worth $115,000. 96.62% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have commented on HSIC shares. Evercore ISI decreased their price target on shares of Henry Schein from $75.00 to $72.00 and set an “in-line” rating on the stock in a research note on Tuesday, July 9th. Baird R W upgraded Henry Schein from a “hold” rating to a “strong-buy” rating in a report on Monday, July 22nd. Barrington Research reissued an “outperform” rating and issued a $92.00 target price on shares of Henry Schein in a report on Friday, July 5th. Piper Sandler reissued an “overweight” rating and issued a $86.00 price objective on shares of Henry Schein in a research note on Friday, June 21st. Finally, Robert W. Baird raised shares of Henry Schein from a “neutral” rating to an “outperform” rating and increased their price target for the company from $81.00 to $92.00 in a report on Monday, July 22nd. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $81.67.

Henry Schein Stock Down 2.4 %

NASDAQ HSIC traded down $1.76 during trading on Friday, reaching $71.02. 3,905,909 shares of the company’s stock traded hands, compared to its average volume of 1,359,569. Henry Schein, Inc. has a 12-month low of $60.01 and a 12-month high of $82.63. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.75 and a quick ratio of 1.02. The firm has a market cap of $9.09 billion, a price-to-earnings ratio of 23.99, a price-to-earnings-growth ratio of 1.80 and a beta of 0.87. The company’s 50 day simple moving average is $68.03 and its two-hundred day simple moving average is $71.80.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, May 7th. The company reported $1.10 EPS for the quarter, topping analysts’ consensus estimates of $1.01 by $0.09. The company had revenue of $3.17 billion during the quarter, compared to the consensus estimate of $3.21 billion. Henry Schein had a net margin of 3.12% and a return on equity of 13.51%. Henry Schein’s revenue for the quarter was up 3.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.21 earnings per share. As a group, sell-side analysts forecast that Henry Schein, Inc. will post 5.16 EPS for the current fiscal year.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.